HORMONE REFRACTORY PROSTATE CANCER AND ITS DEVELOPMENT DURING ANTIANDROGEN THERAPY

<p><em>Mechanisms of development of hormone refractory prostate cancer currently not fully understood.</em></p><p><strong><em>Materials and methods: </em></strong><em>treatment results of 135 prostate cancer patients underwent subcapsular orchiectomy.</em></p><p><strong><em>Results: </em></strong><em>hormone resistance registered at 38 (28.15%) patients, were sensitive to anti-androgenic therapy 97 (71.85%) patients. There are reliable differences between the probability of development of hormone refractory and the patient's age, disease stage and degree of tumor cell differentiation.</em></p><p><strong><em>Conclusion: </em></strong><em>с</em><em>linical developed, laboratory and pathomorphological criteria, the use of which may reliably predict the likelihood of hormone refractory patients with prostate cancer on the background of antiandrogenic treatment.</em>